# Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

> **NCT04064359** · PHASE1 · RECRUITING · sponsor: **Oxford BioTherapeutics Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** OBT076, a CD205-directed antibody-drug conjugate

## Key facts

- **NCT ID:** NCT04064359
- **Lead sponsor:** Oxford BioTherapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04064359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04064359, "Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04064359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*